Angiotensin-converting enzyme inhibitor withdrawal and ACE gene polymorphism

Clinical Nephrology

Volumn 60, Issue 4, 2003, Pages 225-232

  Nonoguchi, H ^a   Kiyama, S ^a   Inoue, H ^a   Nakayama, Y ^a   Inoue, T ^a   Kohda, Y ^a   Machida, K ^a   Tajima, A ^a   Kitamura, K ^a   Miyoshi, T ^a   Shimada, H ^b,c   Tajiri, M ^d   Honda, Y ^e   Tanaka, M ^f   Tomita, K ^a  

^a KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

^b SAISEIKAI KUMAMOTO HOSPITAL   (Japan)

^c Josuikai Shimada Hospital   (Japan)

^d Kumamoto Eye Clinic   (Japan)

^e Kengun Clinic   (Japan)

^f Akebono Clinic   (Japan)

Author keywords

ACE gene; ACE inhibitor; Blood pressure; Chronic renal failure; Proteinuria

Indexed keywords

ALACEPRIL; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BENAZEPRIL; BENIDIPINE; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; CREATININE; DELAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; EFONIDIPINE; ENALAPRIL; IMIDAPRIL; LISINOPRIL; METHYLDOPA; NIFEDIPINE; NILVADIPINE; QUINAPRIL; TEMOCAPRIL;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; CHRONIC GLOMERULONEPHRITIS; CLINICAL ARTICLE; CONTROLLED STUDY; COUGHING; CREATININE BLOOD LEVEL; DETERIORATION; DRUG USE; DRUG WITHDRAWAL; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; GENE INSERTION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HYPERKALEMIA; KIDNEY DYSFUNCTION; MALE; MULTIPLE REGRESSION; NEPHROSCLEROSIS; PROTEINURIA; RENOVASCULAR HYPERTENSION; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS;

EID: 10744221131     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/cnp60225     Document Type: Article

References (19)

1. Agodoa LY, Appel L, Bakris GL, Beck G, Bourgoignie J, Briggs JP et al 2001 Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 285: 2719-2728
2. Fernandez-Llama P, Poch E, Oriola J, Botey A, Rivera F, Revert L 1998 Angiotensin-converting enzyme gene I/D polymorphism in essential hypertension and nephroangiosclerosis. Kidney Int 53: 1743-1747
3. Hansen HP, Rosing P, Tarnow L, Nielsen FS, Jensen BR, Parving H-H 1995 Increased glomerular filtration rate after withdrawal of long-term antihypertensive treatment in diabetic nephropathy. Kidney Int 47: 1726-1731
4. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, Striker G 1994 The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. N Engl J Med 330: 877-884
5. Lan L, Nicolantonio R, Bramich C, Morgan TO 1995 Brief treatment of SHR with an ACE inhibitor fails to cause long-term normotension but markedly increases mortality. Clin Exp Pharmacol Physiol 1: S345-346
6. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, Collaborative Study Group 2001 Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345: 851-860
7. MacFadyen RJ, Struthers AD 1997 The practical assessment of compliance with ACE inhibitor therapy: a novel approach. J Cardiovasc Pharmacol 29: 119-124
8. Mathiesen ER, Hommel E, Hansen HP, Smidt UM, Parving H-H 1999 Randomised controlled trial of long-term efficacy of captopril on preservation of kidney function in normotensive patients with insulin dependent diabetes and microalbuminuria. Br Med J 319: 24-25
9. Miller MA, Texter M, Gmerek A, Robbins J, Shurzinske L, Canter D 1994 Quinapril hydrochloride effects on renal function in patients with renal dysfunction and hypertension: a drug-withdrawal study. Cardiovasc Drug Ther 8: 271-275
10. Nicholls MG, Ikram H, Espiner EA, Maslowski AH, Scandrett MS, Penman T 1982 Hemodynamic and hormonal responses during captopril therapy for heart failure: acute, chronic and withdrawal studies. Am J Cardiol 49: 1497-1501
11. Parving H-H, Jacobsen P, Tarnow L, Rossing P, Lecerf L, Poirier O, Cambien F 1996 Effect of deletion polymorphism of angiotensin-converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin-converting enzyme: observational follow-up study. Br Med J 313: 591-594
12. Pflugfelder PW, Baird MG, Tonkon MJ, DiBianco R, Pitt B 1993 Clinical consequences of angiotensin-converting enzyme inhibitor withdrawal in chronic heart failure: a double-blind, placebo-controlled study of quinapril. J Am Coll Cardiol 22: 1557-1563
13. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F 1990 An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 86: 1343-1346
14. Ruggenenti P, Perna A, Mosconi L, Pisoni R, Remuzzi G 1998 Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN). Kidney Int 53: 1209-1216
15. Ruggenenti P, Perna A, Gherardi G, Garini G, Zoccali C, Salvadori M, Scolari F, Schena FP, Remuzzi G 1999 Renoprotective properties of ACE inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 354: 359-364
16. Ruggenenti P, Perna A, Zoccali C, Gherardi G, Benini R, Testa A, Remuzzi G 2000 Chronic proteinuric nephropathies. II. Outcomes and response to treatment in a prospective cohort of 352 patients: differences between women and men in relation to the ACE gene polymorphism. J Am Soc Nephrol 11: 88-96
17. Ruggenenti P, Perna A, Remuzzi G 2001 ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. J Am Soc Nephrol 12: 2832-2837
18. The Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure 1997 The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 157: 2413-2446
19. van Essen GG, Rensma PL, de Zeeuw D, Sluiter WJ, Scheffer H, Apperloo AJ, de Jong PE 1996 Association between angiotensin-converting enzyme gene polymorphism and failure of renoprotective therapy. Lancet 347: 94-95